ArticleJournal of cellular and molecular medicine2014
A pilot study of angiogenin in heart failure with preserved ejection fraction: a novel potential biomarker for diagnosis and prognosis?
Article in Journal of cellular and molecular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review.European journal of heart failure · 2020Pooled it
- The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis.Disease markers · 2018Pooled it
- Strategies for Monitoring Serum Protein Degradation With an Antibody Array-Based Technology.Journal of clinical laboratory analysis · 2026Article
- Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction.Journal of lipid and atherosclerosis · 2024Review
- The function of tRNA-derived small RNAs in cardiovascular diseases.Molecular therapy. Nucleic acids · 2024Review
- Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes.Cardiovascular diabetology · 2024Article
- The relationship between inflammatory factors and heart failure: evidence based on bidirectional Mendelian randomization analysis.Frontiers in cardiovascular medicine · 2024Article
- Assessment of Cardiac Risk in Women with Autoimmune Disease.Current cardiology reports · 2022Review
- Biomarkers in Acute Heart Failure Syndromes: An Update.Current cardiology reviews · 2022Review
- Towards precision medicine in heart failure.Nature reviews. Cardiology · 2021Review
- Recognized and Potentially New Biomarkers-Their Role in Diagnosis and Prognosis of Cardiovascular Disease.Medicina (Kaunas, Lithuania) · 2021Review
- Finding a Needle in a Haystack: Proteomics in Heart Failure.JACC. Basic to translational science · 2020Review
- Activin B signaling may promote the conversion of normal fibroblasts to scar fibroblasts.Medicine · 2020Observational
- Heart Failure Risk Associated With Rheumatoid Arthritis-Related Chronic Inflammation.Journal of the American Heart Association · 2020Article
- The Use of Antibody Arrays in the Discovery of New Plasma Biomarkers for Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2020Article
- tRNA-Derived Small RNAs and Their Potential Roles in Cardiac Hypertrophy.Frontiers in pharmacology · 2020Review
- A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases.Journal of biomedical science · 2018Review
- Eccrine Sweat as a Biofluid for Profiling Immune Biomarkers.Proteomics. Clinical applications · 2018Article
- Article
- Changes in Blood Components in Aphtha Patients with Excess Heat.Evidence-based complementary and alternative medicine : eCAM · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characteristics of heart failure with preserved ejection fraction (HFPEF) have not yet been fully understood. The objectives of this pilot study are to detect protein expression profile in the sera of HFPEF patients, and to identify potential biomarkers for the disease. Five hundred and seven proteins were detected in the sera of healthy volunteers and patients with either HFPEF or hypertension using antibody microarrays (three in each group). The results showed that the serum concentrations of 17 proteins (e.g. angiogenin, activin A and artemin) differed considerably between HFPEF and non-HFPEF patients (hypertensive patients and healthy controls), while a protein expression pattern distinct from that in non-HFPEF patients was associated with HFPEF patients. The up-regulation of angiogenin in both HFPEF patients with LVEF ≥50% (P = 0.004) and a subset of HFPEF patients with LVEF = 41-49% (P < 0.001) was further validated in 16 HFPEF patients and 16 healthy controls. Meanwhile, angiogenin distinguished HFPEF patients from controls with a mean area under the receiver operating characteristic curve of 0.88 (P < 0.001) and a diagnostic cut-off point of 426 ng/ml. Moreover, the angiogenin levels in HFPEF patients were positively correlated with Lg(N-terminal pro-B-type natriuretic peptide, NT-proBNP) (P < 0.001). In addition, high angiogenin level (≥426 ng/ml) was a predictor of all-cause death within a short-term follow-up duration, but not in the longer term of 36 months. This pilot study indicates that the aforementioned 17 potential biomarkers, such as angiogenin, may hold great promise for both diagnosis and prognosis assessment of HFPEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.